A group of cancer doctors focused on bringing down the cost of treatments by testing whether lower — and cheaper — doses are effective thought they had found a prime candidate in a blood cancer drug called Imbruvica that typically costs $148,000 a year.
Trending:
Science hinted that cancer patients could take less of a $148,000-a-year drug. Its maker tripled the price of a pill.